SEC Comment Letter for Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Feb 5, 2020
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Feb. 5, 2020 · CIK: 0001359931 · Accession: 0000000000-20-001115
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236173
Letter
February 5, 2020 Jesse Shefferman President and Chief Executive Officer ArTara Therapeutics, Inc. 1 Little West 12th Street New York, NY 10014 Re:ArTara Therapeutics, Inc. Registration Statement on Form S-3 Filed January 30, 2020 File No. 333-236173 Dear Mr. Shefferman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Karen Deschaine
Show Raw Text
February 5, 2020
Jesse Shefferman
President and Chief Executive Officer
ArTara Therapeutics, Inc.
1 Little West 12th Street
New York, NY 10014
Re:ArTara Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 30, 2020
File No. 333-236173
Dear Mr. Shefferman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact William Mastrianna, Attorney-Adviser, at (202) 551-3778 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Karen Deschaine